Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 1, 2007, Pages 54-62

  Cysneiros, R M ^a   Farkas, D ^a   Harmatz, J S ^a   Von Moltke, L L ^a   Greenblatt, D J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDOTE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CAFFEINE; PLACEBO; ZOLPIDEM; ZOLPIDEM TARTRATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLITE; PHARMACODYNAMICS; PRIORITY JOURNAL; REACTION TIME; RECALL; SEDATION; TASK PERFORMANCE; VELOCITY;

ADMINISTRATION, ORAL; ADULT; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MENTAL RECALL; PYRIDINES; REACTION TIME; SLEEP;

EID: 34250630391     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100211     Document Type: Article

References (60)

1. Holm, K.J. & Goa, K.L. Zolpidem: an update of its pharmacology therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 59, 865-889 (2000).
2. Darcourt, G., Pringuey, D., Sallière, D. & Lavoisy, J. The safety and tolerability of zolpidem: an update. J. Psychopharmacol. 13, 81-93 (1999).
3. Hoehns, J.D. & Perry, P.J. Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia. Clin. Pharmacy 12, 814-828 (1993).
4. Harrison, T.S. & Keating, G.M. Zolpidem: a review of its use in the management of insomnia. CNS Drugs 19, 65-89 (2005).
5. Undén, M. & Roth-Schechter, B. Next day effects after nighttime treatment with zolpidem: a review. Eur. Psychiatry 11(Suppl 1): 21s-230s (1996).
6. Nowell, P.D., Mazumdar, S., Buysse, D.J., Dew, M.A., Reynolds, C.F. & Kupfer, D.J. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. J. Am. Med. Assoc. 278, 2170-2176 (1997).
7. Lahmeyer, H., Wilcox, C.S., Kann, J. & Leppik, I. Subjective efficacy of zolpidem in outpatients with chronic insomnia: a double-blind comparison with placebo. Clin. Drug Invest. 13, 134-144 (1997).
8. Ware, J.C., Walsh, J.K., Scharf, M.B., Roehrs, T., Roth, T. & Vogel, G.W. Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin. Neuropharmacol. 20, 116-125 (1997).
9. Monti, J.M., Attali, P., Monti, D., Zipfel, A., de la Giclais, B. & Morselli, P.L. Zolpidem and rebound insomnia - a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry 27, 166-175 (1994).
10. Sanger, D.J. et al. Recent developments in the behavioral pharmacology of benzodiazepine (omega) receptors: evidence for the functional significance of receptor subtypes. Neurosci. Biobehav. Rev. 18, 355-372 (1994).
11. Greenblatt, D.J. et al. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J. Pharmacol. Exp. Ther 293, 435-443 (2000).
12. Berlin, I., Warot, D., Hergueta, T., Molinier, P., Bagot, C. & Puech, A.J. Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J. Clin. Psychopharmacol. 13, 100-106 (1993).
13. Rush, C.R. & Griffiths, R.R. Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers. J. Clin. Psychopharmacol. 16, 146-157 (1996).
14. Rush, C.R. Behavioral pharmacology of zolpidem relative to benzodiazepines: a review. Pharmacol. Biochem. Behav. 61, 253-269 (1998).
15. Barone, J.J. & Roberts, H.R. Caffeine consumption. Food Chem. Toxicol. 34, 119-129 (1996).
16. Dorea, J.G. & da Costa, T.H. Is coffee a functional food? Br. J. Nutr. 93, 773-782 (2005).
17. Fisone, G., Borgkvist, A. & Usiello, A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol. Life Sci. 61, 857-872 (2004).
18. Nehlig, A. & Daval, J.L. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res. Rev. 17, 139-170 (1992).
19. Kaplan, G.B., Cotreau, M.M. & Greenblatt, D.J. Effects of benzodiazepine administration on A1 adenosine receptor binding in-vivo and ex-vivo. J. Pharm. Pharmacol. 44, 700-703 (1992).
20. Kaplan, G.B., Greenblatt, D.J., Kent, M.A., Cotreau, M.M., Arcelin, G. & Shader, R.I. Caffeine-induced behavioral stimulation is dose-dependent and associated with A1 adenosine receptor occupancy. Neuropsychopharmacology 6, 145-153 (1992).
21. Kaplan, G.B., Greenblatt, D.J., Kent, M.A. & Cotreau-Bibbo, M.M. Caffeine treatment and withdrawal in mice: relationships between dosage, concentrations, locomotor activity and A1 adenosine receptor binding. J. of Pharmacol. Exp. Ther. 266, 1563-1572 (1993).
22. Biaggioni, I., Paul, S., Puckett, A. & Arzubiaga, C. Caffeine and theophylline as adenosine receptor antagonists in humans. J. Pharmacol. Exp. Ther. 258, 588-593 (1991).
23. Sawynok, J. Pharmacological rationale for the clinical use of caffeine. Drugs 49, 37-50 (1995).
24. Bonnet, M.H., Balkin, T.J., Dinges, D.F., Roehrs, T., Rogers, N.L. & Wesensten, N.J. The use of stimulants to modify performance during sleep loss: a review by the sleep deprivation and Stimulant Task Force of the American Academy of Sleep Medicine. Sleep 28, 1163-1187 (2005).
25. Lorist, M.M. & Tops, M. Caffeine, fatigue, and cognition. Brain Cogn. 53, 82-94 (2003).
26. Caldwell, J.A. & Caldwell, J.L. Fatigue in military aviation: an overview of US military-approved pharmacological countermeasures. Aviat. Space Environ. Med. 76, C39-51 (2005).
27. Polc, P. et al. Caffeine antagonizes several central effects of diazepam. Life Sci. 28, 2265-2275 (1981).
28. File, S.E., Bond, A.J. & Lister, R.G. Interaction between effects of caffeine and lorazepam in performance tests and self-ratings. J. Clin. Psychopharmacol. 2, 102-106 (1982).
29. Mattila, M.E., Mattila, M.J. & Nuotto, E. Caffeine moderately antagonizes the effects of triazolam and zopiclone on the psychomotor performance of healthy subjects. Pharmacol. Toxicol. 70, 286-289 (1992).
30. Johnson, L.C., Spinweber, C.L. & Gomez, S.A. Benzodiazepines and caffeine: effect on daytime sleepiness, performance, and mood. Psychopharmacology (Berl) 101, 160-167 (1990).
31. Loke, W.H., Hinrichs, J.V. & Ghoneim, M.M. Caffeine and diazepam: separate and combined effects on mood, memory, and psychomotor performance. Psychopharmacology 87, 344-350 (1985).
32. Cooper, M., Safran, M. & Eberhardt, M. Caffeine consumption among adults on benzodiazepine therapy: United States 1988-1994. Psychol. Rep. 95, 183-191 (2004).
33. Frary, C.D., Johnson, R.K. & Wang, M.Q. Food sources and intakes of caffeine in the diets of persons in the United States. J. Am. Diet. Assoc. 105, 110-113 (2005).
34. Mattila, M.J., Nurminen, M.L., Vainio, P. & Vanakoski, J. Zolpidem 10mg given at daytime is not antagonized by 300mg caffeine in man. Eur. J. Clin. Pharmacol. 54, 421-425 (1998).
35. Caffeine Content of Foods and Drugs. www.cspinet.org/new/cafchart.htm (2005).
36. von Moltke, L.L. et al. Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br. J. Clin. Pharmacol. 48, 89-97 (1999).
37. Ha, H.R., Chen, J., Krähenbühl, S. & Follath, F. Biotransformation of caffeine by cDNA-expressed human cytochromes P-450. Eur. J. Clin. Pharmacol. 49, 309-315 (1996).
38. Tassaneeyakul, W. et al. Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 2, 173-183 (1992).
39. Tassaneeyakul, W. et al. Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem. Pharmacol. 47, 1767-1776 (1994).
40. Miners, J.O. & Birkett, D.J. The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Gen. Pharmacol. 27, 245-249 (1996).
41. Sesardic, D. et al. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br. J. Clin. Pharmacol. 29, 651-663 (1990).
42. Luurila, H., Kivistö, K.T. & Neuvonen, P.J. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. Eur. J. Clin. Pharmacol. 54, 336-340 (1998).
43. Greenblatt, D.J. et al. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin. Pharmacol. Ther. 64, 661-671 (1998).
44. Culm-Merdek, K.E., von Moltke, L.L., Harmatz, J.S. & Greenblatt, D.J. Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. Br. J. Clin. Pharmacol. 60, 486-493 (2005).
45. Kennedy, J.S., von Moltke, L.L., Harmatz, J.S., Engelhardt, N. & Greenblatt, D.J. Validity of self-reports of caffeine use. J. Clin. Pharmacol. 31, 677-680 (1991).
46. Greenblatt, D.J. et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin. Pharmacol. Ther. 64, 553-561 (1998).
47. Mattila, M.J., Vainio, P., Nurminen, M.L., Vanakoski, J. & Seppala, T. Midazolam 12mg is moderately counteracted by 250mg caffeine in man. Int. J. Clin. Pharmacol. Ther. 38, 581-587 (2000).
48. Roache, J.D. & Griffiths, R.R. Interactions of diazepam and caffeine: behavioral and subjective dose effects in humans. Pharmacol. Biochem. Behav. 26, 801-812 (1987).
49. Mattila, M.J. & Nuotto, E. Caffeine and theophylline counteract diazepam effects in man. Med. Biol. 61, 337-343 (1983).
50. Batejat, D., Coste, O., Van Beers, P., Lagarde, D., Pierard, C. & Beaumont, M. Prior sleep with zolpidem enhances the effect of caffeine or modafinil during 18 h continuous work. Aviat. Space Environ. Med. 77, 515-525 (2006).
51. von Moltke, L.L. et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J. Pharmacol. Exp Ther 276, 370-379 (1996).
52. Greenblatt, D.J., Harmatz, J.S., Gouthro, T.A., Locke, J. & Shader, R.I. Distinguishing a benzodiazepine agonist (triazolam) from a non-agonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. Clin. Pharmacol. Ther 56, 100-111 (1994).
53. Kaplan, G.B. et al. Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J. Clin. Pharmacol. 37, 693-703 (1997).
54. DiMascio, A. & Buie, D.H. Psychopharmacology of chlorphentermine and D-amphetamine. A comparative study of their effects in normal males. Clin. Pharmacol. Ther. 5, 174-184 (1964).
55. Scavone, J.M., Greenblatt, D.J., Harmatz, J.S. & Shader, R.I. Kinetic and dynamic interaction of brotizolam and ethanol. Br. J. Clin. Pharmacol. 21, 197-204 (1986).
56. Greenblatt, D.J., Abernethy, D.R., Morse, D.S., Shader, R.I. & Harmatz, J.S. Clinical importance of the interaction of diazepam and cimetidine. N Engl J Med 310, 1639-1643 (1984).
57. Shader, R.I., Dreyfuss, D., Gerrein, J.R., Harmatz, J.S., Allison, S.J. & Greenblatt, D.J. Sedative effects and impaired learning and recall following single oral doses of lorazepam. Clin. Pharmacol. Ther. 39, 526-529 (1986).
58. Durol, A.L.B. & Greenblatt, D.J. Analysis of zolpidem in human plasma by high-performance liquid chromatography with fluorescence detection: application to single-dose pharmacokinetic studies. J. Anal. Toxicol. 21, 388-392 (1997).
59. Kennedy, J.S., LeDuc, B.W., Scavone, J.M., Harmatz, J.S., Shader, R.I. & Greenblatt, D.J. The pharmacokinetics of intravenous caffeine: comparison of high performance liquid chromatographic and gas chromatographic methods. J. Chromatogr. 422, 274-280 (1987).
60. Kaplan, G.B., Greenblatt, D.J., LeDuc, B.W., Thompson, M.L. & Shader, R.I. Relationship of plasma and brain concentrations of caffeine and metabolites to benzodiazepine receptor binding and locomotor activity. J. Pharmacol. Exp. Ther. 248, 1078-1083 (1989).